Amarin Corporation, a biopharmaceutical company, has announced a drop in its third-quarter revenue for 2024, largely due to the rising competition from generic drugs in the U.S. market. The company’s CEO, Aaron Berg, underlined the strategic emphasis on increasing access to its cardiovascular disease treatment, VASCEPA/VAZKEPA,